Article citationsMore>>
Moresco, R.M., Cavallaro, R., Messa, C., Bravi, D., Gobbo, C., Galli, L., Lucignani, G., Colombo, C., Rizzo, G., Velona, I., Smeraldi, E. and Fazio, F. (2004) Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. Journal of Psycho- pharmacology, 18, 355-365.
has been cited by the following article:
-
TITLE:
Very-high-dose olanzapine for treatment-resistant schizophrenia
AUTHORS:
Jean-Marie Batail, Sophie Bleher, Clément Lozachmeur, Gabriel Robert, Bruno Millet, Dominique Drapier
KEYWORDS:
Schizophrenia; Treatment Resistance; High-Dose Olanzapine; Treatment Tolerance
JOURNAL NAME:
Open Journal of Psychiatry,
Vol.2 No.4,
October
31,
2012
ABSTRACT: Treatment-resistant schizophrenia has an extremely negative impact on mental health and social life. If clozapine, the gold standard treatment, fails, there are very few options left. The literature suggests that high-dose olanzapine (20 - 60 mg/day) is a possible alternative. We report two cases in which very high doses of olanzapine were administered, with significant clinical improvements above 60 mg/day. Clinical, metabolic and cardiac tolerance was good. This report highlights the usefulness of very-high-dose olanzapine in treatment-resistant schizophrenia. The main hypotheses concerning the psychopharmacological mechanisms of very-high-dose olanzapine are discussed.
Related Articles:
-
Pierpaolo Perrucci
-
Sarah Tasneem, Lester Lipsky, Reda Ammar, Howard Sholl
-
Bernardin Ahouty, Mathurin Koffi, David Courtin, Ilboudo Hamidou, Didier Sokouri, Innocent Abé, Laure Gineau, Thomas Konan, Lingué Kouakou, Tidou Abiba Sanogo, Enock Matovu, Bruno Bucheton, Vincent Jamonneau, Simon-Pierre N’Guetta
-
Affi Jeanne Bongoua-Devisme, Wondouet Hippolyte Kpan, Pla Kouassi Adou, Franck Michaël Lemonou Bahan, Konan-Kan Hippolith Kouadio, Anselme Kan Louis Koko
-
Brou Julien Kouakou, Koffi Christophe Kobenan, Kouadio Emmanuel N’Goran, Malanno Kouakou, Nogbou Ferdinand Amangoua, Diane Ester Gnapi